Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01667068 |
Recruitment Status
:
Completed
First Posted
: August 17, 2012
Last Update Posted
: October 28, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Since the introduction of antiretroviral therapy life expectancy of HIV-infected persons is rising. Different cohorts are observing an increased risk for cardiovascular diseases in this aging HIV-infected population. Traditional cardiovascular risk factors like smoking are more frequent in HIV-infected persons. For example chronic inflammation due to HIV-infection and metabolic disorders also caused by some antiretroviral substances as special non-traditional risk factors in HIV-infected persons can influence the development of cardiovascular diseases additionally. Therefore new research focus in special risk profile associated with HIV-infection or antiretroviral treatment and prevention for HIV-infected patients is developing.
This present study is an ongoing prospective regional multicenter trial that was conducted to analyse the incidence, prevalence and clinical course of cardiovacular disorders in HIV-infected out-patients.
Cardiac disorders witch are associated with HIV are pericarditis, pleural effusion, pulmonary hypertension, dilated cardiomyopathy, heart failure, myocarditis, bacterial endocarditis and heart valve disorders. In addition to previously stated disorders of the heart, the premature atherosclerosis of coronary arteries, a further even more important disease of the heart in this patient population, went into the focus of most HIV-researchers and physicians.
Condition or disease | Intervention/treatment |
---|---|
Coronary Heart Disease Heart Failure HIV AIDS Metabolic Syndrome | Other: Comprehensive non invasive cardiovascular examination |
Study Type : | Observational |
Actual Enrollment : | 1481 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | HIV-HEART STUDY: A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk in HIV-infected Patients |
Study Start Date : | April 2012 |
Actual Primary Completion Date : | April 2014 |
Actual Study Completion Date : | October 2014 |

Group/Cohort | Intervention/treatment |
---|---|
Regional Ruhrgebiets Cohort
HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
|
Other: Comprehensive non invasive cardiovascular examination
|
- Cardiovascular Diseases in HIV-infected Patients [ Time Frame: Baseline up to 7.5 follow-up to ]The detection of prevalence, aetiology, progression and severity of cardiovascular diseases - especially of coronary artery disease in HIV-infected patients.
- Cardiovascular Disorders in HIV-infected Patients HIV-HEART [ Time Frame: Baseline up to 5 years follow-up ]Complementary the study also investigates the impact of classic cardiovascular risk factors like gender, age, blood fat and also new HIV-specific risk factors of coronary artery disease like viral-load, CD4-cell count and stage of the infection. The HIV-HEART study will focus the impact of medication including cardiovascular and antiretroviral medication. Further secondary objectives will be examined, including economic costs and the subjectively quality of life of subjects with and without cardiovascular diseases in this patient population.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age > 18 years
- Known HIV-infection
- Written informed consent
Exclusion Criteria:
- Acute cardiovascular disease
- Unstable hemodynamic status in the three weeks before inclusion
- Pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01667068
Germany | |
University Hospital of Bochum, Department of Dermatology | |
Bochum, Germany, 44791 | |
HIV Outpatient Department | |
Dortmund, Germany, 44137 | |
Health Center | |
Duisburg, Germany, 47249 | |
University Hospital, Department of Dermatology and Venerology | |
Essen, Germany, 45147 | |
University Hospital, West German Heart Center Essen | |
Essen, Germany, 45147 | |
Clinical Coordinating Center Leipzig | |
Leipzig, Germany, 04107 |
Principal Investigator: | Stefan Esser, MD | University Hospital, Essen | |
Principal Investigator: | Till Neumann Neumann, MD | University Hospital, Essen |
Publications of Results:
Responsible Party: | Stefan Esser M.D., Academic Director, University Hospital, Essen |
ClinicalTrials.gov Identifier: | NCT01667068 History of Changes |
Other Study ID Numbers: |
12-4970-BO |
First Posted: | August 17, 2012 Key Record Dates |
Last Update Posted: | October 28, 2014 |
Last Verified: | October 2014 |
Keywords provided by Stefan Esser M.D., University Hospital, Essen:
Cardiac Diseases HIV-Infection AIDS Antiretroviral Therapy Cardiovascular Medication |
Risk Factors coronary heart disease heart failure metabolic syndrome |
Additional relevant MeSH terms:
Heart Failure Heart Diseases Metabolic Syndrome X Coronary Disease Coronary Artery Disease Myocardial Ischemia Cardiovascular Diseases |
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases |